Carter Percy H, Tebben Andrew J
Research & Development, Bristol-Myers Squibb Company, Princeton, New Jersey, USA.
Methods Enzymol. 2009;461:249-79. doi: 10.1016/S0076-6879(09)05412-3.
Chemokine receptor antagonists have potential applications in fields as diverse as oncology, immunology, cardiovascular diseases, and virology. Although the chemokine receptors are G-protein-coupled receptors, their cognate ligands are small proteins (8 to 12 kDa), and so inhibiting the ligand/receptor interaction has been challenging. In this chapter, we review the use of receptor mutagenesis to probe the allosteric nature of chemokine receptor binding by small molecule antagonists. We then demonstrate how two different homology modeling templates--a balloon-expanded form of rhodopsin and a modified form of beta(2)-adrenergic receptor--can be used to rationalize the mutagenesis data. With these templates, new models are presented for several antagonist/receptor interactions previously studied in the literature, including those for CCR1, CCR2, and CCR5. We discuss the strengths of both approaches and offer ideas for how the templates themselves can be used in the absence of mutagenesis data to rationalize structure-activity relationships.
趋化因子受体拮抗剂在肿瘤学、免疫学、心血管疾病和病毒学等诸多领域都有潜在应用。尽管趋化因子受体是G蛋白偶联受体,但其同源配体是小蛋白(8至12 kDa),因此抑制配体/受体相互作用一直具有挑战性。在本章中,我们回顾了利用受体诱变来探究小分子拮抗剂与趋化因子受体结合的变构性质。然后我们展示了两种不同的同源建模模板——视紫红质的气球膨胀形式和β2 -肾上腺素能受体的修饰形式——如何用于合理解释诱变数据。利用这些模板,我们提出了文献中先前研究的几种拮抗剂/受体相互作用的新模型,包括CCR1、CCR2和CCR5的模型。我们讨论了这两种方法的优点,并就如何在没有诱变数据的情况下使用模板本身来合理解释构效关系提供了思路。